JP5642333B2 - アルツハイマー病の予防または治療のための併用療法およびそのキット - Google Patents

アルツハイマー病の予防または治療のための併用療法およびそのキット Download PDF

Info

Publication number
JP5642333B2
JP5642333B2 JP2007520813A JP2007520813A JP5642333B2 JP 5642333 B2 JP5642333 B2 JP 5642333B2 JP 2007520813 A JP2007520813 A JP 2007520813A JP 2007520813 A JP2007520813 A JP 2007520813A JP 5642333 B2 JP5642333 B2 JP 5642333B2
Authority
JP
Japan
Prior art keywords
app
binding
kit
antibody
amyloid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007520813A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008506665A (ja
JP2008506665A5 (cg-RX-API-DMAC7.html
Inventor
フランク・マットナー
ヴァルター・シュミット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affiris AG
Original Assignee
Affiris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris AG filed Critical Affiris AG
Publication of JP2008506665A publication Critical patent/JP2008506665A/ja
Publication of JP2008506665A5 publication Critical patent/JP2008506665A5/ja
Application granted granted Critical
Publication of JP5642333B2 publication Critical patent/JP5642333B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
JP2007520813A 2004-07-13 2005-07-06 アルツハイマー病の予防または治療のための併用療法およびそのキット Expired - Fee Related JP5642333B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0118504A AT500483B1 (de) 2004-07-13 2004-07-13 Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
ATA1185/2004 2004-07-13
PCT/EP2005/053224 WO2006005706A2 (de) 2004-07-13 2005-07-06 Kombinationstherapie zur vorbeugung oder behandlung der alzheimer´schen erkrankung sowie kit hierfür

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013010868A Division JP2013116903A (ja) 2004-07-13 2013-01-24 アルツハイマー病の予防または治療のための併用療法およびそのキット

Publications (3)

Publication Number Publication Date
JP2008506665A JP2008506665A (ja) 2008-03-06
JP2008506665A5 JP2008506665A5 (cg-RX-API-DMAC7.html) 2008-08-14
JP5642333B2 true JP5642333B2 (ja) 2014-12-17

Family

ID=35115768

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007520813A Expired - Fee Related JP5642333B2 (ja) 2004-07-13 2005-07-06 アルツハイマー病の予防または治療のための併用療法およびそのキット
JP2013010868A Pending JP2013116903A (ja) 2004-07-13 2013-01-24 アルツハイマー病の予防または治療のための併用療法およびそのキット

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013010868A Pending JP2013116903A (ja) 2004-07-13 2013-01-24 アルツハイマー病の予防または治療のための併用療法およびそのキット

Country Status (14)

Country Link
US (2) US7935348B2 (cg-RX-API-DMAC7.html)
EP (1) EP1765388B8 (cg-RX-API-DMAC7.html)
JP (2) JP5642333B2 (cg-RX-API-DMAC7.html)
KR (1) KR101158600B1 (cg-RX-API-DMAC7.html)
CN (1) CN101022825B (cg-RX-API-DMAC7.html)
AT (1) AT500483B1 (cg-RX-API-DMAC7.html)
AU (1) AU2005261687B8 (cg-RX-API-DMAC7.html)
CA (1) CA2577332C (cg-RX-API-DMAC7.html)
DK (1) DK1765388T3 (cg-RX-API-DMAC7.html)
ES (1) ES2414872T3 (cg-RX-API-DMAC7.html)
PL (1) PL1765388T3 (cg-RX-API-DMAC7.html)
PT (1) PT1765388E (cg-RX-API-DMAC7.html)
TW (1) TW200602072A (cg-RX-API-DMAC7.html)
WO (1) WO2006005706A2 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003303198A1 (en) 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
AU2007336770A1 (en) * 2006-12-22 2008-07-03 Genentech, Inc. DR6 antibodies inhibiting the binding of DR6 to APP, and uses thereof in treating neurological disorders
US8895004B2 (en) * 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
WO2009054537A1 (ja) * 2007-10-25 2009-04-30 Kagoshima University アミロイドβペプチドのミミック分子を用いたペプチドワクチン
ES2332846B1 (es) 2007-10-26 2010-07-08 Grifols, S.A. Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.
AT506819B1 (de) * 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
AT506820B1 (de) * 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
US20100030196A1 (en) * 2008-07-29 2010-02-04 Medtronic, Inc. Apheresis of a target molecule from cerebrospinal fluid
CN102271669A (zh) * 2008-11-13 2011-12-07 基因改造有限责任公司 非大脑组织中β-淀粉样肽负载的改性
CN102264411B (zh) 2008-12-22 2014-10-22 学校法人藤田学园 Aβ除去材料、Aβ除去器和Aβ除去系统
US20110033463A1 (en) * 2009-08-06 2011-02-10 Medtronic, Inc. Apheresis, administration of agent, or combination thereof
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
JP5843345B2 (ja) 2010-07-08 2016-01-13 旭化成メディカル株式会社 β−アミロイド除去システム
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
RS53496B1 (sr) 2011-10-04 2015-02-27 Affiris Ag POSTUPAK ZA DETEKCIJU Aβ-SPECIFIČNIH ANTITELA U BIOLOŠKOM UZORKU
MX352749B (es) 2011-11-01 2017-12-06 Modgene Llc Composiciones y metodos para la reduccion de la carga amiloide-beta.
CN110133300B (zh) * 2012-03-18 2022-02-25 镜株式会社 疾病样品分析装置、分析系统及分析方法
DE102012108598A1 (de) * 2012-09-14 2014-04-10 Forschungszentrum Jülich GmbH Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung
JP2015518474A (ja) * 2012-04-05 2015-07-02 フォルシュングスツェントルム ユーリッヒ ゲゼルシャフト ミット ベシュレンクテル ハフツングForschungszentrum Juelich GmbH 血液、血液生産物及び器官を処置する方法
CN104380111B (zh) 2012-04-05 2017-08-29 于利希研究中心有限公司 包含多价结合淀粉样β蛋白的D‑肽的聚合物及其应用
KR101416954B1 (ko) * 2012-09-12 2014-07-16 한양대학교 산학협력단 조혈세포 분화 유도 방법
CN106103467B (zh) * 2014-03-11 2019-12-31 艾克斯-马赛大学 与细胞膜神经节苷脂相互作用的嵌合肽
CN106466298A (zh) * 2015-08-14 2017-03-01 上海交通大学医学院 一种单唾液酸四己糖神经节苷脂修饰的重组脂蛋白及其应用
CN109414482A (zh) * 2016-05-12 2019-03-01 俄亥俄州创新基金会 用于治疗神经退行性疾病的肽和方法
US20200164008A1 (en) * 2017-07-17 2020-05-28 Spark Therapeutics, Inc. Apheresis methods and uses
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
CN115957324A (zh) * 2021-10-12 2023-04-14 首都医科大学宣武医院 外周CLU作为靶点在降低脑Aβ中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476715A (en) 1989-10-03 1995-12-19 Fresenius Ag Particulate adsorbent for the removal of biomacromolecules such as LDL and endotoxins from whole blood in extracorporeal circuits
AU691297B2 (en) 1994-05-13 1998-05-14 Miltenyi Biotec Gmbh Sterile and pyrogen-free columns coupled to protein for binding and removal of substances from blood
EP0886085B1 (en) 1997-06-18 2002-04-03 Morse Tec Europe S.p.A. Sprocket wheel with improved tooth profile for greater silentness
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
JP2002533169A (ja) 1998-12-29 2002-10-08 オキュロジックス コーポレイション レオロジー的処置方法および関連するアフェレーシスシステム
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
DE60217107T2 (de) 2001-06-20 2007-08-23 Ramot At Tel Aviv University Ltd. Mehrantigenisches peptid enthaltend mehrere kopien eines epitopes von einem ablagerungsformenden polypeptid und dessen verwendung
US20050227941A1 (en) * 2001-12-17 2005-10-13 Karen Duff Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases
WO2004013172A2 (en) 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
AU2003303198A1 (en) * 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
KR20050118669A (ko) * 2003-02-01 2005-12-19 뉴랄랩 리미티드 가용성 a-베타에 대한 항체를 생성하기 위한 능동 면역화
AT413336B (de) * 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
US20050158306A1 (en) * 2004-01-16 2005-07-21 Halikas James A. Treatment for neuro-degenerative disease by a blood cleansing system using monoclonal antibodies
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
AT413946B (de) * 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
AT500835B1 (de) * 2004-09-13 2007-12-15 Affiris Forschungs & Entwicklungs Gmbh Cholinestertransport-protein-mimotop als atherosklerose-medikament

Also Published As

Publication number Publication date
JP2008506665A (ja) 2008-03-06
DK1765388T3 (da) 2013-07-22
US20080051690A1 (en) 2008-02-28
TWI350173B (cg-RX-API-DMAC7.html) 2011-10-11
AU2005261687B2 (en) 2011-02-17
HK1103354A1 (en) 2007-12-21
EP1765388B1 (de) 2013-04-17
CN101022825B (zh) 2015-02-04
WO2006005706A8 (de) 2006-11-16
ES2414872T8 (es) 2014-11-06
EP1765388A2 (de) 2007-03-28
CN101022825A (zh) 2007-08-22
AT500483B1 (de) 2006-01-15
CA2577332C (en) 2014-12-09
AU2005261687B8 (en) 2011-07-21
EP1765388B8 (de) 2013-05-29
ES2414872T3 (es) 2013-07-23
AT500483A4 (de) 2006-01-15
PL1765388T3 (pl) 2013-09-30
WO2006005706A2 (de) 2006-01-19
KR101158600B1 (ko) 2012-07-09
TW200602072A (en) 2006-01-16
US20110201987A1 (en) 2011-08-18
US7935348B2 (en) 2011-05-03
KR20070036158A (ko) 2007-04-02
JP2013116903A (ja) 2013-06-13
AU2005261687A1 (en) 2006-01-19
WO2006005706A3 (de) 2006-07-20
CA2577332A1 (en) 2006-01-19
PT1765388E (pt) 2013-05-24

Similar Documents

Publication Publication Date Title
JP2013116903A (ja) アルツハイマー病の予防または治療のための併用療法およびそのキット
JP5989074B2 (ja) アミロイドーシス治療のための化合物
CA3192383A1 (en) .beta.-amyloid vaccine for the treatment of alzheimer's disease
US20240148782A1 (en) Treatment and prevention of alzheimer's disease (ad)
IL300346A (en) TAU vaccine for the treatment of Alzheimer's disease
Triplett et al. Active immunization targeting amyloid β for the treatment of Alzheimer’s disease
KR102460465B1 (ko) 알츠하이머병(ad)의 치료 및 예방
US9295719B2 (en) Method for treating amyloid disease
KR102388363B1 (ko) 알츠하이머병(ad)의 치료 및 예방
HK1103354B (en) Combination therapy for preventing or treating alzheimer's disease, and kit therefor
US20250134973A1 (en) Liposomes Containing Phosphorylated Tau Peptides for Inducing Sustained Immune Responses
WO2006048295A1 (en) Composition compri sing vlp and amyloid - beta peptide
Decourtb et al. Active Immunization Targeting Amyloid β for the Treatment of AlzheimerLs
Agadjanyan et al. Editorial [Hot Topic: Active and Passive Aβ-Immunotherapy: Preclinical and Clinical Studies and Future Directions: Part I (Guest Editors: Michael G. Agadjanyan and David H. Cribbs)]
CN118613496A (zh) 安全施用Tau磷酸肽缀合物的方法
Cribbs et al. Editorial [Hot Topic: Active and Passive Aβ-Immunotherapy: Preclinical and Clinical Studies and Future Directions: Part II (Guest Editors: Michael G. Agadjanyan and David H. Cribbs)]
WO2006097416A1 (en) Compounds for use in the prevention and treatment of alzheimer's disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111028

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20111205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20111205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120416

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120423

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120515

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120522

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120614

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120621

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120925

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141029

R150 Certificate of patent or registration of utility model

Ref document number: 5642333

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees